First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers

被引：0

作者：

Thierry Landre

Gaetan Des Guetz

Kader Chouahnia

Cherifa Taleb

Alain Vergnenègre

Christos Chouaïd

机构：

[1] Hôpital René-Muret,UCOG 93

[2] APHP,Service d’Oncologie Médicale

[3] Centre Hospitalier Delafontaine,Service d’Oncologie Médicale

[4] Hôpital Avicenne,Service d’Oncogériatrie

[5] APHP,Service de Pneumologie

[6] Hôpital René-Muret,undefined

[7] APHP,undefined

[8] Service d’Oncologie Médicale,undefined

[9] Unité d’Oncologie Thoracique,undefined

[10] Centre Hospitalier Intercommunal (CHI) Créteil,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷

关键词：

Non-small-cell lung cancer; PD-L1; Anti-PD-1/PD-L1; Immunotherapy; Meta-analysis; Management; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：441 / 448

页数：7

共 50 条

[31] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A.
Andreozzi, M.
Ludovini, V.
Rossi, E.
Capodanno, A.
Landi, L.
Tibaldi, C.
Minuti, G.
Salvini, J.
Coppi, E.
Chella, A.
Fontanini, G.
Filice, M. E.
Tornillo, L.
Incensati, R. M.
Sani, S.
Crino, L.
Terracciano, L.
Cappuzzo, F.
BRITISH JOURNAL OF CANCER, 2015, 112 (01) : 95 - 102
[32] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A D'Incecco
M Andreozzi
V Ludovini
E Rossi
A Capodanno
L Landi
C Tibaldi
G Minuti
J Salvini
E Coppi
A Chella
G Fontanini
M E Filice
L Tornillo
R M Incensati
S Sani
L Crinò
L Terracciano
F Cappuzzo
British Journal of Cancer, 2015, 112 : 95 - 102
[33] Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
Li, Lingling
Pi, Chenghui
Yan, Xin
Lu, Jiangyue
Yang, Xuhui
Wang, Chunyu
Li, Xiaoyan
Zhang, Sujie
Zhang, Zhibo
Sun, Yi
Hu, Yi
FRONTIERS IN ONCOLOGY, 2021, 11
[34] PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First-Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study
Huang, Riqing
Li, Haifeng
Li, Shuo
Shu, Ditian
Chen, Rishang
Zheng, Zhousan
Gao, Tinghua
Chen, Meiting
Hu, Anqi
Huang, Yunjie
Zheng, Qiufan
An, Xin
Xue, Cong
Cai, Yuchen
Shi, Yanxia
MEDCOMM, 2025, 6 (03):
[35] Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae, Young Kwang
Pan, Alan
Davis, Andrew A.
Raparia, Kirtee
Mohindra, Nisha A.
Matsangou, Maria
Giles, Francis J.
CLINICAL LUNG CANCER, 2016, 17 (05) : 350 - 361
[36] Chemotherapy plus PD-1/PD-L1 inhibitor versus chemotherapy alone in first-line treatment for recurrent or advanced endometrial cancer: A systematic review and meta-analysis of randomized controlled trials
de Liz, Caio Dabbous
Maia, Melissa
Fonseca Alves, Ana Caroline
Mendes da Silva, Isadora Mamede
Oliveira, Joao Pedro
Ferreira de Oliveira, Audrey Cabral
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, Xin
Kang, Kuan
Chen, Pan
Zeng, Zhaoyang
Li, Guiyuan
Xiong, Wei
Yi, Mei
Xiang, Bo
MOLECULAR CANCER, 2024, 23 (01)
[38] Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Aggen, David H.
Drake, Charles G.
Rini, Brian I.
CLINICAL CANCER RESEARCH, 2020, 26 (09) : 2087 - 2095
[39] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
Isla, Dolores
Sanchez, Alfredo
Casal, Joaquin
Cobo, Manuel
Majem, Margarita
Reguart, Noemi
Zugazagoitia, Jon
Bernabe, Reyes
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
[40] PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
Chen, Shubin
Wei, Haowen
Zhao, Wenhua
Jiang, Wei
Ning, Ruiling
Zhou, Shaozhang
Tan, Liping
Wang, Huilin
Su, Cuiyun
He, Jianbo
Zeng, Aiping
Zhao, Yun
Yu, Qitao
FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 →